{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:49:20Z","timestamp":1791524960905,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Americas"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lana.2026.101596","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T13:28:41Z","timestamp":1786195721000},"page":"101596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Projected lives saved and economic value of mRNA cancer immunotherapies in the United States"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1370-8350","authenticated-orcid":false,"given":"Chad R.","family":"Wells","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Bawden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0710-1341","authenticated-orcid":false,"given":"Yang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilori","family":"Bilori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Potter-Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamia","family":"Ayaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-0227","authenticated-orcid":false,"given":"Seyed M.","family":"Moghadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan C.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2059-6716","authenticated-orcid":false,"given":"Alison P.","family":"Galvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lana.2026.101596_bib1","series-title":"HHS Winds Down mRNA Vaccine Development Under BARDA","year":"2025"},{"key":"10.1016\/j.lana.2026.101596_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.lana.2026.101596_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.lana.2026.101596_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.43127","article-title":"Return on investment of the COVID-19 vaccination campaign in New York City","volume":"5","author":"Sah","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.lana.2026.101596_bib5","doi-asserted-by":"crossref","first-page":"e073747","DOI":"10.1136\/bmj-2022-073747","article-title":"US public investment in development of mRNA covid-19 vaccines: retrospective cohort study","volume":"380","author":"Lalani","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.lana.2026.101596_bib6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0140-6736(23)02463-7","article-title":"Individualised neoantigen cancer vaccine therapy","volume":"403","author":"Terai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.lana.2026.101596_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41435-024-00305-3","article-title":"Neoantigen-specific mRNA\/DC vaccines for effective anticancer immunotherapy","volume":"25","author":"Zhang","year":"2024","journal-title":"Genes Immun"},{"key":"10.1016\/j.lana.2026.101596_bib8","first-page":"1","article-title":"Neoantigen-based cancer vaccines: current innovations, challenges and future directions in personalized immunotherapy","volume":"1","author":"Ahmed","year":"2024","journal-title":"Targeted Cancer Therapy Connect"},{"key":"10.1016\/j.lana.2026.101596_bib9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.lana.2026.101596_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.lana.2026.101596_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.lana.2026.101596_bib13","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.lana.2026.101596_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1108511","article-title":"Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy","volume":"5","author":"Rittig","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lana.2026.101596_bib15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.lana.2026.101596_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bjc.6602321","article-title":"Years of life lost (YLL) from cancer is an important measure of population burden \u2014 and should be considered when allocating research funds","volume":"92","author":"Burnet","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lana.2026.101596_bib17","author":"Kearsley"},{"key":"10.1016\/j.lana.2026.101596_bib18","article-title":"Mortality risk valuation","year":"2014","journal-title":"Environ Econ"},{"key":"10.1016\/j.lana.2026.101596_bib19","author":"Kearsley"},{"key":"10.1016\/j.lana.2026.101596_bib20","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/jnci\/djn434","article-title":"How should we value lives lost to cancer?","volume":"100","author":"Ramsey","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lana.2026.101596_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1470-2045(25)00096-8","article-title":"Personalised cancer vaccines and new regulatory struggles","volume":"26","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lana.2026.101596_bib22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.lana.2026.101596_bib23","article-title":"A vaccine for pancreatic cancer treatment?","author":"Lowe","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.lana.2026.101596_bib24","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3390\/pharmaceutics17080992","article-title":"Artificial intelligence-driven strategies for targeted delivery and enhanced stability of RNA-based lipid nanoparticle cancer vaccines","volume":"17","author":"Bhujel","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.lana.2026.101596_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17111882","article-title":"Current progress and future perspectives of RNA-based cancer vaccines: a 2025 update","volume":"17","author":"Magoola","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lana.2026.101596_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102333","article-title":"Quality by design for mRNA platform purification based on continuous oligo-dT chromatography","volume":"35","author":"Qu","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.lana.2026.101596_bib27","series-title":"Risks of Cuts to mRNA Vaccine Development","year":"2025"}],"container-title":["The Lancet Regional Health - Americas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X26002267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667193X26002267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:54:25Z","timestamp":1791521665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667193X26002267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"alternative-id":["S2667193X26002267"],"URL":"https:\/\/doi.org\/10.1016\/j.lana.2026.101596","relation":{},"ISSN":["2667-193X"],"issn-type":[{"value":"2667-193X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Projected lives saved and economic value of mRNA cancer immunotherapies in the United States","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Americas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lana.2026.101596","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101596"}}